Rebecca Whittaker

Rebecca Whittaker is a Features Writer specialising in Health. She joined MailOnline in September 2022 after working on local papers, including the Oxford Mail. Rebecca covers a range of health topics for the online publication and has written about various treatments and conditions.

Biography:  https://www.dailymail.co.uk/profile-228/rebecca-whittaker.html

84%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

50%

Examples:

  • Ozempic and its sister drug Wegovy work by triggering the body to bind to a receptor called the glucagon-like peptide-1 (GLP-1), a protein that triggers the release of hormones in the brain which keep the stomach full and tell the body to stop eating and avoid cravings, but they may also delay stomach emptying, preventing oral contraceptives from being absorbed effectively.
  • Semaglutide reduces the risk of heart attack and stroke by maintaining a healthy weight but also drastically reduces alcohol intake.
  • Trials are assessing the effects of semaglutide versus placebo in people with early Alzheimer's disease.

Deceptions

50%

Examples:

  • But the researchers at University of Oklahoma School of Community Medicine and Oklahoma State University Center for Health Sciences also found they reduced their alcohol intake.
  • It's not just food Ozempic puts you off, it may also drastically reduce your desire to drink alcohol.
  • Ozempic and its sister drug Wegovy work by triggering the body to bind to a receptor called the glucagon-like peptide-1 (GLP-1), a protein that triggers the release of hormones in the brain which keep the stomach full and tell the body to stop eating and avoid cravings.
  • Semaglutide also works by delaying the stomach from emptying, which could prevent oral contraceptives from being absorbed effectively by the body.
  • Trials are assessing the effects of semaglutide versus placebo in people with early Alzheimer's disease.

Recent Articles

GLP-1 Agonists: Transformative Weight Loss Drugs with Unexpected Health Benefits - From Smoking Addiction to Mental Health and Alzheimer's Prevention

GLP-1 Agonists: Transformative Weight Loss Drugs with Unexpected Health Benefits - From Smoking Addiction to Mental Health and Alzheimer's Prevention

Broke On: Wednesday, 17 April 2024 GLP-1 agonists, such as Ozempic and Mounjaro, are transformative weight loss drugs with unexpected benefits beyond shedding pounds. These medications impact mental health by prolonging satiety and potentially reducing the urge to smoke. However, concerns over psychiatric side effects have emerged. Experts suggest that patients may not be getting sufficient nutrients on these appetite-suppressing drugs, contributing to reported side effects. GLP-1 agonists also show promise in treating obesity, reducing heart attack and stroke risk, improving fertility, and preventing Alzheimer's disease.